Remarks and conclusions on ovarian cancer treatment
- 1 July 2001
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 11 (s1) , 77-81
- https://doi.org/10.1046/j.1525-1438.2001.11(suppl.1)sup1077.x
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Impact of new non-cytotoxics in the treatment of ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)International Journal of Gynecologic Cancer, 2001
- The integration of docetaxel into first-line chemotherapy for ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- High dose chemotherapy in ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- Gemcitabine in the treatment of ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- A combination of a fixed dose of carboplatin plus paclitaxel and adriamycin in first line therapy for advanced ovarian cancer and suboptimal surgical cytoreduction. A phase I trial of the Spanish group for ovarian cancer research and treatment (GEICO)European Journal Of Cancer, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Guidelines for Surgical Staging of Ovarian CancerObstetrical & Gynecological Survey, 1994